Clinical Data

Durham – November 06, 2026 -- Brii Biosciences (2137.HK) reported that 41.9% of participants (62/148) in its Phase 2b ENRICH study achieved hepatitis B surface antigen (HBsAg) loss at end of treatment (EOT), with 32.4% (48/148) sustaining it 24 weeks later. The data were presented in three late-breaking sessions at the AASLD Liver Meeting in Denver, running November 5 to 9, 2026.

ENRICH reproduces the BRII-179 priming effect seen in ENSURE Cohort 4

ENRICH prospectively tested a strategy first identified in Cohort 4 of the ENSURE study, where BRII-179-experienced participants, particularly those developing anti-HBs responses, showed higher functional cure rates. Participants received BRII-179 every 3 or 2 weeks for 12 weeks before elebsiran and pegylated interferon alpha (PEG-IFNα). Results across both dose regimens matched the ENSURE observations.

Stockholm – October 30, 2026 -- Eisai will present five years of Clarity AD data on lecanemab (Leqembi) at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, November 16-19, 2026, according to its partner BioArctic AB (Nasdaq Stockholm: BIOA B). The dataset spans the core and long-term extension phases and is one of the longest follow-up sets reported to date for an approved anti-amyloid Alzheimer's therapy.

LEADER study tests lecanemab in US clinical practice three years after approval

A symposium on Wednesday, November 18, 11:00-11:40 AM ET, will cover the retrospective, multicenter LEADER study. The study draws on real-world data from different types of US treatment centers, three years after FDA approval.

Three analyses are scheduled: utilization and outcomes from initiation through maintenance therapy, sex-based outcomes, and at-home subcutaneous administration.

SHANGHAI – October 27, 2026 -- Henlius' serplulimab combined with chemotherapy delivered a median overall survival (OS) of 12.4 months versus 10.2 months for atezolizumab plus chemotherapy in the U.S. ASTRIDE study of first-line extensive-stage small cell lung cancer (ES-SCLC). The company presented the data at the European Society for Medical Oncology (ESMO) Congress 2026.

ASTRIDE shows a numerical OS edge but no formal superiority test

The hazard ratio was 0.82 (95% CI, 0.56-1.20), at a median follow-up of 14.1 months and a data cutoff of February 18, 2026. The trial was descriptive, with no formal hypothesis testing for superiority or noninferiority planned.

One-year OS rates were 52.4% for serplulimab and 41.4% for atezolizumab. Two-year OS rates were 32.2% and 17.6%, respectively. The serplulimab arm had more patients with liver metastasis (49.5% vs 40.0%).

Indianapolis – October 15, 2026 -- More than one in four ulcerative colitis (UC) patients (27.7%) treated with Eli Lilly and Company's Omvoh (mirikizumab-mrkz) achieved comprehensive disease control at one year, compared with 14% on placebo, according to a post hoc analysis of the LUCENT-2 trial.

In the VIVID-1 Crohn's disease trial, 20.4% of Omvoh-treated patients reached corticosteroid-free deep remission, versus 2% on placebo. Lilly will present both analyses at United European Gastroenterology (UEG) Week 2026.

New York – October 14, 2026 -- Fesarius Therapeutics will present its DermiSphereTM hDRT dermal regeneration template at Plastic Surgery The Meeting (PSTM) 2026, October 15–18 at the George R. Brown Convention Center in Houston, Texas. The company will also appear at an event hosted by ASPS Ventures, the medtech venture fund.

Fesarius schedules a one-hour scientific symposium on October 17

The session, "From Benchtop to Bedside - Advancing Dermal Regeneration with Hydrogel Technology," runs 3:30–4:30 p.m. CDT in Innovation Theater B, Exhibit Hall DE. It will cover the science and clinical application of DermiSphereTM hDRT, including its dual-density microarchitecture, recently published clinical data and surgeon experience across complex wound and reconstructive applications.

San Carlos – October 12, 2026 -- Noah Medical's Galaxy System achieved a diagnostic yield of 92-96% in one hospital's early field experience and 96% in another's, according to whitepapers covering 165 patient procedures and 190 lesions. The data comes from D. Kyle Hogarth, MD, of the University of Chicago Medical Center, and Amit Mahajan, MD, of Inova Fairfax Hospital.

Small, peripheral lesions dominate the Galaxy System caseload

Average lesion size ranged from 14mm to 16mm, and more than one-third of lesions were 10mm or smaller. Roughly 88% of lesions biopsied by Hogarth and 75% of those biopsied by Mahajan sat in the outer third of the lung or at the pleura.

Average procedure time did not exceed 46 minutes at either site.

Braintree, Mass. – October 12, 2026 -- Braintree Laboratories, part of Sebela Pharmaceuticals, reported that its investigational P-CAB tegoprazan delivered statistically significant gains over placebo in both heartburn and regurgitation in the 783-patient Phase 3 TRIUMpH-NERD study. The company describes it as the first P-CAB to show clinical improvement in both hallmark non-erosive reflux disease (NERD) symptoms in a prospective U.S. Phase 3 trial.

Both tegoprazan doses meet primary and key secondary endpoints

TRIUMpH-NERD (NCT05587322) was a randomized, double-blind, placebo-controlled, multicenter study. Patients received tegoprazan 50 mg, tegoprazan 100 mg or placebo once daily for four weeks, followed by a 20-week extension. The primary endpoint was the percentage of 24-hour heartburn-free days through Week 4. Days without nighttime heartburn was a key secondary endpoint, and regurgitation was a prespecified exploratory endpoint.

Washington – October 02, 2026 -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) is presenting three new data sets on its monoclonal antibody imsidolimab at the European Academy of Dermatology and Venereology (EADV) Annual Meeting in Vienna, Austria, running September 30 through October 3, 2026.

Vanda shows imsidolimab cuts neutrophil levels rapidly in GPP patients

Poster P1769 (Abstract AS-4323) reports a rapid reduction in neutrophils and the neutrophil percentage-to-albumin ratio following imsidolimab treatment in patients with generalized pustular psoriasis (GPP), a rare orphan skin condition.

Immunogenicity data on imsidolimab presented in separate poster

A second poster, P1784 (Abstract AS-2420), details the immunogenicity profile of imsidolimab in GPP patients.

Plainsboro, New Jersey – – September 30, 2026 -- Adults with overweight or obesity who switched from injectable GLP-1 therapies to the oral Wegovy pill lost an average of 4.0 kg (8.8 lb) over three months, according to new real-world data from Novo Nordisk's OCTANE study presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan on September 30, 2026.

Patients switching to the oral formulation saw rapid weight-loss gains after three months

The retrospective analysis of 194 patients on the Ro telehealth platform found that 40.7% achieved weight loss of 5% or more within three months of switching from injectable semaglutide or tirzepatide to once-daily oral semaglutide (p0.001). The proportion of participants classified with a BMI of 30 kg/m2 or higher fell by 21.6 percentage points, dropping from 87.1% at baseline to 65.5% at the three-month mark.

Stockholm – September 24, 2026 -- Sobi (STO: SOBI) will present new clinical data on its rare-disease drug Gamifant (emapalumab) at the 2026 Annual Meeting of the Histiocyte Society (HS2026), running September 26-29 in Rotterdam, the Netherlands, with a pooled survival analysis nominated for the meeting's top poster prize.

Pooled transplant-survival analysis earns Robert J. Arceci Prize nomination

The accepted abstract set includes a new pooled analysis of pre- and post-transplant survival outcomes in primary haemophagocytic lymphohistiocytosis (HLH), drawing on data across three prospective trials. Sobi said the analysis was selected as one of the ten highest-scoring poster abstracts at HS2026 and has been nominated for the Robert J. Arceci Prize for Best Poster.